Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.

PubWeight™: 0.80‹?›

🔗 View Article (PMC 2832747)

Published in Pharmacogenomics on February 01, 2010

Authors

Craig P Hersh1

Author Affiliations

1: Channing Laboratory & Division of Pulmonary & Critical Care Medicine, Brigham & Women's Hospital, 181 Longwood Avenue, Boston, MA 02115, USA. craig.hersh@channing.harvard.edu

Articles cited by this

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86

Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med (2001) 27.83

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med (2004) 18.60

A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature (2008) 18.21

A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19

The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med (2004) 17.08

Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17

Replicating genotype-phenotype associations. Nature (2007) 16.11

A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA (1994) 10.46

A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med (2003) 10.40

BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax (1997) 9.69

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med (1987) 8.41

Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. MMWR Surveill Summ (2002) 7.07

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J (1995) 7.03

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med (1995) 6.99

A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93

Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet (1981) 6.48

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17

Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med (1996) 5.82

Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med (2001) 5.76

Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38

Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest (2007) 5.01

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med (1980) 4.81

Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med (2006) 4.11

Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J (2006) 3.89

Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax (2003) 3.62

Risk indexes for exacerbations and hospitalizations due to COPD. Chest (2007) 3.55

Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry (2008) 3.12

Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.09

Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS One (2009) 3.00

The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med (2009) 2.60

Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol (2004) 2.33

The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant (2009) 2.20

Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet (2004) 2.14

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax (2003) 2.11

Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol (2005) 2.08

Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med (2001) 2.03

Associations of IL6 polymorphisms with lung function decline and COPD. Thorax (2009) 2.00

The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet (2002) 1.99

Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.98

Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med (2007) 1.94

Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest (2002) 1.83

A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med (2005) 1.82

Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med (1999) 1.80

Risk and severity of COPD is associated with the group-specific component of serum globulin 1F allele. Chest (2004) 1.77

Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Am J Respir Crit Care Med (2002) 1.76

Association of IL-1beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. Thorax (2001) 1.72

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J (2003) 1.70

The natural history of chronic obstructive pulmonary disease. Eur Respir J (2006) 1.66

Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest (1986) 1.61

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest (2008) 1.60

Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment Trial. Chest (2008) 1.59

Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet (2009) 1.52

Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med (2005) 1.52

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J (2009) 1.41

Computed tomographic-based quantification of emphysema and correlation to pulmonary function and mechanics. COPD (2008) 1.38

Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. Hum Mol Genet (2003) 1.36

Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33

Xenobiotic metabolizing enzyme gene polymorphisms predict response to lung volume reduction surgery. Respir Res (2007) 1.27

Lung function loss, smoking, vitamin C intake, and polymorphisms of the glutamate-cysteine ligase genes. Am J Respir Crit Care Med (2008) 1.21

The many "small COPDs": COPD should be an orphan disease. Chest (2008) 1.17

Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD (2007) 1.12

Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations. Am J Respir Crit Care Med (2008) 1.09

Outcomes and health-related quality of life following hospitalization for an acute exacerbation of COPD. Respirology (2005) 1.07

A single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.06

Glutathione S-transferase genotypes modify lung function decline in the general population: SAPALDIA cohort study. Respir Res (2007) 1.06

Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun (2003) 1.02

Leptin receptor polymorphisms and lung function decline in COPD. Eur Respir J (2009) 1.00

Polymorphisms in the beta2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers. Thorax (2003) 0.99

Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 0.99

Pharmacogenetics of asthma. Curr Opin Pulm Med (2009) 0.99

Pharmacogenetics of smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet (2010) 0.99

Polymorphisms in the IL13, IL13RA1, and IL4RA genes and rate of decline in lung function in smokers. Am J Respir Cell Mol Biol (2003) 0.99

Transforming growth factor-beta receptor-3 is associated with pulmonary emphysema. Am J Respir Cell Mol Biol (2009) 0.98

COPD and declining FEV1--time to divide and conquer? N Engl J Med (2008) 0.98

Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? Eur Respir J (2009) 0.98

Polymorphic variation in surfactant protein B is associated with COPD exacerbations. Eur Respir J (2008) 0.98

Bronchodilator responsiveness and serum total IgE levels in families of probands with severe early-onset COPD. Eur Respir J (1999) 0.96

Clinical consequences of ADRbeta2 polymorphisms. Pharmacogenomics (2008) 0.95

Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung (2008) 0.95

Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. Respirology (2008) 0.95

Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med (2000) 0.92

Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. Respir Med (2008) 0.88

Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest (2007) 0.88

Lung volume reduction surgery: a meta-analysis of randomized clinical trials. Treat Respir Med (2005) 0.87

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J (2008) 0.87

Time to define the disorders of the syndrome of COPD. Lancet (2009) 0.86

CT scanning-based phenotypes vary with ADRB2 polymorphisms in chronic obstructive pulmonary disease. Respir Med (2008) 0.86

Heme oxygenase-1 gene promoter polymorphism and decline in lung function in Japanese men. Thorax (2006) 0.85

ABCC1 polymorphisms contribute to level and decline of lung function in two population-based cohorts. Pharmacogenet Genomics (2009) 0.84

The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD (2009) 0.84

Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology (2008) 0.83

Association of Hck genetic polymorphisms with gene expression and COPD. Hum Genet (2006) 0.81

Promise of pharmacogenomics in smoking cessation. Pharmacogenomics (2009) 0.77

Beta2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD. Med Sci Monit (2008) 0.77

A novel polymorphism in CDC6 is associated with the decline in lung function of ex-smokers in COPD. Biochem Biophys Res Commun (2009) 0.77